4.8 Article

Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells

Journal

CANCER CELL
Volume 35, Issue 2, Pages 221-+

Publisher

CELL PRESS
DOI: 10.1016/j.ccell.2019.01.002

Keywords

-

Funding

  1. University Cancer Research Fund at the University of North Carolina at Chapel Hill, United States
  2. National Cancer Institute, United States [R01-CA193140-03, R03CA223886]
  3. Rivkin Center for Ovarian Cancer, United States
  4. Department of Defense, United States [W81XWH-16-1-0501, W81XWH-16-1-0500]
  5. National Institute of Dental & Craniofacial Reseacrh, United States [R01DE028172]
  6. National Cancer Institute Center Core support grant, United States [5P30CA016086-41]
  7. National Cancer Institute Cancer core grant, United States [P30-CA016086-40]

Ask authors/readers for more resources

The high expression across multiple tumor types and restricted expression in normal tissues make B7-H3 an attractive target for immunotherapy. We generated chimeric antigen receptor (CAR) T cells targeting B7-H3 (B7-H3.CAR-Ts) and found that B7-H3.CAR-Ts controlled the growth of pancreatic ductal adenocarcinoma, ovarian cancer and neuroblastoma in vitro and in orthotopic and metastatic xenograft mouse models, which included patient-derived xenograft. We also found that 4-1BB co-stimulation promotes lower PD-1 expression in B7-H3.CAR-Ts, and superior antitumor activity when targeting tumor cells that constitutively expressed PD-L1. We took advantage of the cross-reactivity of the B7-H3.CAR with murine B7-H3, and found that B7-H3.CAR-Ts significantly controlled tumor growth in a syngeneic tumor model without evident toxicity. These findings support the clinical development of B7-H3.CAR-Ts.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available